Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-612 Vaccine in Adults
NCT04683224Phase 3Withdrawn
- Sponsor
- Vaxxinity
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of UB-612 in coronavirus disease 2019 (COVID-19), sponsored by Vaxxinity. Planned start Feb 2021; status: withdrawn.
02
Drugs
UB-612
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04683224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683224.